Industry sponsors are the companies that lead and pay for a clinical trial; academic sponsors are the university hospitals, health bodies and investigators that run studies of their own. If you sell services to industry sponsors, the second group is mostly noise, and it can dominate a list. Of the recruiting interventional trials on ClinicalTrials.gov that run only in the UK, 81% are led by sponsors the registry classes as "Other" rather than industry (example built from the ClinicalTrials.gov API, 24 Oct 2026). A UK user at a CRO customer put it plainly when looking at a sponsor list: the vast majority are university hospitals or academics, which are not really that applicable to us.
They are not wrong, and it is not a data-quality problem. It is what the registry is for. Public trial registries exist to make every interventional study visible, whoever runs it. Commercial sponsorship is one slice of that, and in some regions it is the smaller slice.
Here is how sponsor class works, why the mix changes with how you search, and what you can do about it today.
Sponsor class in the registry
ClinicalTrials.gov records an organization type for the lead sponsor and for each collaborator, and its search filters group them as funder types. The registry's data structure defines the lead sponsor as the organization or person who initiates the study and has authority and control over it. The values that matter for a commercial BD team are:
| Funder type | What it usually means | Worth prospecting? |
|---|---|---|
| Industry | A company is the lead sponsor and is paying | Yes, this is the target |
| NIH | US federal funding, academic or government-run | Rarely |
| Other US Federal | Other federal agencies | Rarely |
| Other | Universities, hospitals, foundations, individual investigators | Usually not, with exceptions |
The trap sits in that last row. "Other" is a very large bucket. It holds university hospitals and investigator-initiated studies, which you probably do not want. It also holds small private biotechs that did not classify themselves as industry, foundations that fund real outsourced work, and the occasional well-funded non-profit that buys services exactly like a company does.
So sponsor class is a strong first filter and a weak final one. Treat it as a way to cut volume, not as a definition of your addressable market.
Lead sponsor versus collaborator
The second thing that trips people up is the difference between the lead sponsor and the collaborators.
A study can be led by a university and collaborated on by a pharmaceutical company. The company may be supplying the drug, funding part of the work, or both. If you filter on lead sponsor only, you will miss these entirely. If you filter on any-sponsor, you will pull in every study where a large pharma name appears in a supporting role, and most of those are not buying anything.
The practical rule: filter on lead sponsor for outbound, then review collaborators separately when you are researching a named account. A company that shows up as a collaborator on six academic studies in your therapeutic area is running a real programme, even if it leads none of them.
Why the mix depends on how you search
The share of academic sponsors in your results depends less on the country than on which trials you pull. We ran the same query against the ClinicalTrials.gov API on 24 Oct 2026: recruiting, interventional studies, grouped by lead sponsor class.
| Search | Studies | Led by industry | Led by "Other" |
|---|---|---|---|
| Any site in the UK | 1,929 | 61% | 36% |
| Sites in the UK only | 668 | 14% | 81% |
| Any site in Germany | 1,856 | 60% | 38% |
| Sites in Germany only | 588 | 15% | 85% |
| Any site in the US | 17,807 | 24% | 71% |
| Sites in the US only | 15,157 | 13% | 81% |
Search by trial site and a UK or German result set is mostly industry, because multinational company trials recruit there. Narrow to studies that run in one country only, which is what a locally focused list tends to pull in, and sponsors classed as "Other" take over, in the US as much as in Europe. If your territory is defined by where sponsors are based rather than where trials recruit, expect the academic share to be high and plan for review time.
Doing it today
Sponsor class is one input rather than the whole answer. The approach that works is a combination of filters:
- Filter by company attributes rather than study attributes. Filter the sponsor universe by therapeutic area, highest phase and modality. Companies that carry a modality and a development pipeline are, almost by definition, not university hospitals.
- Use HQ country to shape the list, then budget review time for the academic names that remain. Planning by region works the same way as territory planning by state.
- Scan the names. This sounds crude and it is, but it is fast. Academic sponsors announce themselves in their names: university, hospital, centre hospitalier, universitätsklinikum, foundation, institute.
- Keep a rejection list. Whatever tool you use, record the academic sponsors you have already dismissed so nobody on your team re-qualifies them next quarter. This is the step most teams skip and the one that compounds.
The edge cases nobody solves
No filter resolves the edge cases, because they are genuine ambiguity rather than missing data. A foundation that funds and outsources a Phase 2 programme looks like an academic sponsor in the registry and behaves like an industry one in your pipeline. A small biotech that classified itself as "Other" during registration is an industry sponsor wearing the wrong label.
Any vendor promising you a clean industry-only universe is either filtering aggressively and hiding the misses, or has not looked closely at the data. The realistic goal is a list that is mostly on-target before a human reads it, with a short review pass for the rest. The same caution applies to preclinical and stealth biotechs, which often do not appear in a registry at all.
Frequently asked questions
How do I filter academic sponsors out? Filter the sponsor universe on therapeutic area, phase, modality and HQ. That excludes most academic centres in one step, because a university hospital does not carry a development pipeline the way a company does, and it is a better first cut than sponsor class alone.
Does the skew affect US searches too? Yes. In our 24 Oct 2026 ClinicalTrials.gov query, 81% of recruiting interventional studies that run only in the US were led by sponsors classed as "Other", the same share as UK-only studies. The NIH funder type does make federal funding easy to spot in the US.
Should I ignore academic sponsors entirely? No. Some academic centres and foundations outsource real work on real budgets, and a few are excellent long-term accounts. The point is not to exclude them permanently but to stop them crowding out industry sponsors in a prospecting list, which is a different job from account management.
What about collaborator relationships? Filter on lead sponsor for outbound, then check collaborators when researching a named account, ideally before the RFP goes out. A company appearing repeatedly as a collaborator in your therapeutic area has a programme worth understanding even if it leads no studies itself.
If your territory is European and your list keeps filling with hospitals, it is worth seeing what a filtered sponsor universe looks like on your actual therapeutic areas. That is the fastest way to judge whether the current filters get you close enough. See how it works for CRO business development.
